![Michael Wortley](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Michael Wortley
Plus aucun poste en cours
Profil
Michael D.
Wortley is currently employed at Vinson & Elkins LLP since 2004.
He previously worked at Johnson & Wortley PC as Chairman & President from 1978 to 1995.
He also served as an Independent Director at Pioneer Natural Resources Co. from 2015 to 2022 and as Chief Legal Officer & Executive Vice President at Reata Pharmaceuticals, Inc. from 2015 to 2023.
Wortley received his undergraduate degree from Southern Methodist University, his graduate degree from SMU Dedman School of Law, and another graduate degree from The University of North Carolina at Charlotte.
Anciens postes connus de Michael Wortley
Sociétés | Poste | Fin |
---|---|---|
REATA PHARMACEUTICALS, INC. | Conseiller Juridique Général | 26/09/2023 |
PIONEER NATURAL RESOURCES COMPANY | Directeur/Membre du Conseil | 25/05/2022 |
Johnson & Wortley PC | Président | 01/01/1995 |
Formation de Michael Wortley
Southern Methodist University | Undergraduate Degree |
SMU Dedman School of Law | Graduate Degree |
The University of North Carolina at Charlotte | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 3 |
---|---|
Pioneer Natural Resources Co.
![]() Pioneer Natural Resources Co. Oil & Gas ProductionEnergy Minerals Pioneer Natural Resources Co. operates as an independent oil and gas exploration and production company. The firm engages in hydrocarbon exploration in the Cline Shale. It focuses on the operation of the Permian Basin, Eagle Ford Shale, Rockies, and West Panhandle projects. The company was founded by Scott Douglas Sheffield on April 2, 1997, and is headquartered in Irving, TX. | Energy Minerals |
Reata Pharmaceuticals, Inc.
![]() Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX. | Health Technology |
Johnson & Wortley PC |